marked.bio

Company

Servier

2 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

vorasidenib 1

Trials

2 of 2 trials shown

  1. Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

    Active, not recruiting Phase 3 Servier Started 2024Primary completion 2026-05 NCT06780930

    vorasidenib FDA EU

    Have confirmed IDH1 (IDH1 R132H/C/G/S/L mutation variants tested) or IDH2 (IDH2 R172K/M/W/S/G mutation variants tested) g…

    IDH1/2 mutationResidual or Recurrent Grade 2 IDH Mutant Glioma

  2. S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation

    Not yet recruiting Phase 1/2 Servier Started 2026Primary completion 2029-08 NCT07722312

    S243249 600mgS243249 400mgS243249 450mgS243249 300mg

    Confirmation of KMT2At, NUP98t, or NPM1c mutation using next generation sequencing (NGS), fluorescence in situ hybridization (FISH), or pol…

    NPM1 mutationRelapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Myeloid Leukemia